 |
3P BIOPHARMACEUTICALS |
CRO / CMO |
Strain development and RCB manufacturing in microbial expression systems (Bacteria and yeast) |
5RTM |
Strain development and RCB manufacturing in microbial expression systems (Bacteria and yeast)
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Stability studies services |
5RTM |
Stability studies services
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Mammalian cell line development |
5RTM |
Mammalian cell line development
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP Cell Bank Manufacturing (MCB, WCB) and storage |
5RTM |
GMP Cell Bank Manufacturing (MCB, WCB) and storage
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Analytical methods development, qualification and validation platform for NBE and Biosimilars |
5RTM |
Analytical methods development, qualification and validation platform for NBE and Biosimilars
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Process development, optimization and formulation development |
5RTM |
Process development, optimization and formulation development
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Technology transfer, Scale-up and non-GMP manufacturing services |
5RTM |
Technology transfer, Scale-up and non-GMP manufacturing services
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP manufacturing mammalian services (up to 2000L) |
5RTM |
GMP manufacturing mammalian services (up to 2000L)
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Cell therapy services |
5RTM |
Cell therapy services
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP manufacturing microbial services (up to 1000L) |
5RTM |
GMP manufacturing microbial services (up to 1000L)
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
GMP manufacturing services for Clinical Trials and Commercial |
5RTM |
GMP manufacturing services for Clinical Trials and Commercial
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
DS & DP Testing and release |
5RTM |
DS & DP Testing and release
Type:
CRO / CMO
|
|
3P BIOPHARMACEUTICALS |
CRO / CMO |
Comparability studies services |
5RTM |
Comparability studies services
Type:
CRO / CMO
|
 |
53Biologics |
CRO / CMO |
Process development (USP & DSP): optimization of the production process and purification phases. The company goal is to get all bioprocess stages established, optimized, characterized and ready to be transferred for manufacturing. |
2PreV |
Process development (USP & DSP): optimization of the production process and purification phases. The company goal is to get all bioprocess stages established, optimized, characterized and ready to be transferred for manufacturing.
Type:
CRO / CMO
|
|
53Biologics |
CRO / CMO |
Analytics: implement, develop and qualify the analytical methods needed for the characterization of the protein of interest. The company has a broad range of techniques available for the physic-chemical characterization of recombinant proteins |
3CV |
Analytics: implement, develop and qualify the analytical methods needed for the characterization of the protein of interest. The company has a broad range of techniques available for the physic-chemical characterization of recombinant proteins
Type:
CRO / CMO
|
|
53Biologics |
CRO / CMO |
Contract Productions: offers a manufacturing structure fully customizable and adaptable to fulfill its clients need in time, cost and manner in the production capacity for your recombinant protein. |
3CV |
Contract Productions: offers a manufacturing structure fully customizable and adaptable to fulfill its clients need in time, cost and manner in the production capacity for your recombinant protein.
Type:
CRO / CMO
|
|
53Biologics |
CRO / CMO |
Cell line transformation, banking and characterization (cGMP if required): producing recombinant proteins (monoclonal, fusion, chimeric and fragment antibodies, biosimilars, enzymes, anticoagulants, vaccines..) in a wide range of microbial expression sys |
3CV |
Cell line transformation, banking and characterization (cGMP if required): producing recombinant proteins (monoclonal, fusion, chimeric and fragment antibodies, biosimilars, enzymes, anticoagulants, vaccines..) in a wide range of microbial expression sys
Type:
CRO / CMO
|
 |
ADM BIOPOLIS |
CRO / CMO |
Contract manufacturing: upstream and downstream development, analytical development, scale-up |
5RTM |
Contract manufacturing: upstream and downstream development, analytical development, scale-up
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO |
Metagenomics and metabolomic analysis |
5RTM |
Metagenomics and metabolomic analysis
Type:
CRO / CMO
|
|
ADM BIOPOLIS |
CRO / CMO
Screening |
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials |
5RTM |
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials
Type:
CRO / CMO
Screening
|
|
ADM BIOPOLIS |
CRO / CMO
Screening |
Novel functional probiotics screening, validation and production |
1R+D |
Novel functional probiotics screening, validation and production
Type:
CRO / CMO
Screening
|
|
ADM BIOPOLIS |
CRO / CMO |
Recombinant protein expression systems |
1R+D |
Recombinant protein expression systems
Type:
CRO / CMO
|
 |
APTUS Biotech |
Drug Delivery
Enabling Technologies
Screening |
AptusBiotech has built an aptamer development platform, from cell lines to protein, peptides or small molecule selections procedures, providing high quality candidates for pre-clinical trials with an innovative drug development process based on aptamers |
1R+D |
AptusBiotech has built an aptamer development platform, from cell lines to protein, peptides or small molecule selections procedures, providing high quality candidates for pre-clinical trials with an innovative drug development process based on aptamers
Type:
Drug Delivery
Enabling Technologies
Screening
|
 |
Arthex Biotech |
Drug Delivery |
ENTRY Platform: Enhancing antimiR delivery to treat unmet diseases.
ARTHEx biotech launches ENTRY,a platform that will allow it to advance its pipeline of drugs by providing tissue-enriched delivery of antimiRs.
The ENTRY platform improves drug delivery |
2PreV |
ENTRY Platform: Enhancing antimiR delivery to treat unmet diseases.
ARTHEx biotech launches ENTRY,a platform that will allow it to advance its pipeline of drugs by providing tissue-enriched delivery of antimiRs.
The ENTRY platform improves drug delivery
Type:
Drug Delivery
|
 |
Biobide |
CRO / CMO
Screening |
Zebrafish Toxicity screening assays for Pharma, Biotech, Chemical, Agrochemical, Tobacco, Nutraceutical, and Cosmetic companies for candidate selection in early discovery and development phases:Developmental toxicity, Neurotoxicity, Cardiotoxicity, Hepati |
5RTM |
Zebrafish Toxicity screening assays for Pharma, Biotech, Chemical, Agrochemical, Tobacco, Nutraceutical, and Cosmetic companies for candidate selection in early discovery and development phases:Developmental toxicity, Neurotoxicity, Cardiotoxicity, Hepati
Type:
CRO / CMO
Screening
|
|
Biobide |
CRO / CMO |
Zebrafish Lines Management:In parallel to the increase in the use of zebrafish as an animal model, Biobide has developed a Zebrafish Sperm Cryopreservation and In vitro fertilization protocol to answer the need to implement a program to reduce the number |
5RTM |
Zebrafish Lines Management:In parallel to the increase in the use of zebrafish as an animal model, Biobide has developed a Zebrafish Sperm Cryopreservation and In vitro fertilization protocol to answer the need to implement a program to reduce the number
Type:
CRO / CMO
|
|
Biobide |
CRO / CMO
Screening |
Zebrafish Efficacy Assays for different therapeutic areas in drug discovery: Neurodegenerative diseases, Oncology, Cardiovascular, Immune diseases, Infectious diseases, Rare diseases (DMD, ALS...), other models, etc. |
5RTM |
Zebrafish Efficacy Assays for different therapeutic areas in drug discovery: Neurodegenerative diseases, Oncology, Cardiovascular, Immune diseases, Infectious diseases, Rare diseases (DMD, ALS...), other models, etc.
Type:
CRO / CMO
Screening
|
|
Biobide |
CRO / CMO
Screening |
Zebrafish Disease Model Generation and Target Identification and Validation for different therapeutic areas through morpholinos, transgenesis (Tol2 Kit), CRISPR/Cas9, TALENS, chemically induced models, xenograft models, etc. |
5RTM |
Zebrafish Disease Model Generation and Target Identification and Validation for different therapeutic areas through morpholinos, transgenesis (Tol2 Kit), CRISPR/Cas9, TALENS, chemically induced models, xenograft models, etc.
Type:
CRO / CMO
Screening
|
 |
BIONET INGENIERÍA |
Enabling Technologies |
Smart functional modules to be coupled to bioreactor technologies in a Plug&Play fashion. Examples of these are the Continuous Process Modules for performance of continuous processing, and the bBreath module for the analysis of gas composition at the exha |
5RTM |
Smart functional modules to be coupled to bioreactor technologies in a Plug&Play fashion. Examples of these are the Continuous Process Modules for performance of continuous processing, and the bBreath module for the analysis of gas composition at the exha
Type:
Enabling Technologies
|
|
BIONET INGENIERÍA |
CRO / CMO
Enabling Technologies
Screening |
Rocking bioreactor with patentend 2D movement (Cell-tainer Biosolutions GmbH) for microbial and cell culture applications. Lab and Pilot scale. |
5RTM |
Rocking bioreactor with patentend 2D movement (Cell-tainer Biosolutions GmbH) for microbial and cell culture applications. Lab and Pilot scale.
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
BIONET INGENIERÍA |
CRO / CMO
Enabling Technologies
Screening |
Glass labscale bioreactors |
5RTM |
Glass labscale bioreactors
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
BIONET INGENIERÍA |
Enabling Technologies
Screening |
Labscale Tangential Flow Filtration units, very flexible for R&D since it allows the integration of all types of membranes: ceramic, hollow fiber and cassettes |
5RTM |
Labscale Tangential Flow Filtration units, very flexible for R&D since it allows the integration of all types of membranes: ceramic, hollow fiber and cassettes
Type:
Enabling Technologies
Screening
|
.png) |
Biotechnology Assets |
CRO / CMO
Screening |
BBD-ZFM. Biobide's platfom for Toxicity and Efficacy Assays of active compounds in Zebra Fish (validated and included in international regulations). Long track record of services to pharmas, agro-food, and cosmetic companies. |
5RTM |
BBD-ZFM. Biobide's platfom for Toxicity and Efficacy Assays of active compounds in Zebra Fish (validated and included in international regulations). Long track record of services to pharmas, agro-food, and cosmetic companies.
Type:
CRO / CMO
Screening
|
|
Biotechnology Assets |
Drug Delivery
Enabling Technologies |
CLICK-CAR. Universal, multi-target and cost-effective SPLIT-CAR for increasing efficacy of CAR-T treatments (higher persistence and lower toxicity). |
2PreV |
CLICK-CAR. Universal, multi-target and cost-effective SPLIT-CAR for increasing efficacy of CAR-T treatments (higher persistence and lower toxicity).
Type:
Drug Delivery
Enabling Technologies
|
|
Biotechnology Assets |
Drug Delivery
Enabling Technologies |
VACC-ZERA platform for improvement of the immune response raised by recombinant vaccines (proteins or DNA/RNA vaccines). Elimination of cold-chain for storage by formation of metastable nanostructures comprising the antigen before delivery. |
3CV |
VACC-ZERA platform for improvement of the immune response raised by recombinant vaccines (proteins or DNA/RNA vaccines). Elimination of cold-chain for storage by formation of metastable nanostructures comprising the antigen before delivery.
Type:
Drug Delivery
Enabling Technologies
|
|
Biotechnology Assets |
|
CLICK´N CUT. Based on our proprietary set of split-inteins, and together with a top bioprocessing company, we have developed Click'N Cut resin as a universal affinity purification system to obtain tag-less proteins in just one step. For research and biop |
2PreV |
CLICK´N CUT. Based on our proprietary set of split-inteins, and together with a top bioprocessing company, we have developed Click'N Cut resin as a universal affinity purification system to obtain tag-less proteins in just one step. For research and biop
Type:
|
|
Biotechnology Assets |
CRO / CMO
Enabling Technologies |
CLICK-GENE. SPLITTERA platform for gene therapy and gene editing. Overcomes gene size limitations of viral vectors by in-vivo covalent reconstitution of large proteins mediated by split inteins. |
2PreV |
CLICK-GENE. SPLITTERA platform for gene therapy and gene editing. Overcomes gene size limitations of viral vectors by in-vivo covalent reconstitution of large proteins mediated by split inteins.
Type:
CRO / CMO
Enabling Technologies
|
|
Biotechnology Assets |
CRO / CMO
Enabling Technologies
Screening |
CLICK-BIO. SPLITTERA Split-intein site-specific protein conjugation platform. Allows functionalization of any Ab format or protein. Capacity to obtain tailor-made antibodies libraries with unique features. |
5RTM |
CLICK-BIO. SPLITTERA Split-intein site-specific protein conjugation platform. Allows functionalization of any Ab format or protein. Capacity to obtain tailor-made antibodies libraries with unique features.
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Biotechnology Assets |
Drug Delivery
Enabling Technologies |
CLICK-VLP. Split Intein-mediated ANTIGEN DISPLAY for VLPs surface functionalization. It’s a “glue“ for functioning VLPs, overcoming limitations in production of classical VLPs. |
3CV |
CLICK-VLP. Split Intein-mediated ANTIGEN DISPLAY for VLPs surface functionalization. It’s a “glue“ for functioning VLPs, overcoming limitations in production of classical VLPs.
Type:
Drug Delivery
Enabling Technologies
|
|
Biotechnology Assets |
CRO / CMO
Drug Delivery
Enabling Technologies |
CLICK-TARGET. SPLITTERA technology for gene therapy. Allows the decoration of viral particles with covalently bound effectors making possible to target viral particles to specific tissues. |
2PreV |
CLICK-TARGET. SPLITTERA technology for gene therapy. Allows the decoration of viral particles with covalently bound effectors making possible to target viral particles to specific tissues.
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
|
 |
Celtarys Research |
CRO / CMO
Enabling Technologies |
Develop and commercialize new chemical tools to spread the use of fluorescence-based methods in drug discovery. These fluorescent ligands are used in target-based drug discovery for High throughput screening campaigns. |
5RTM |
Develop and commercialize new chemical tools to spread the use of fluorescence-based methods in drug discovery. These fluorescent ligands are used in target-based drug discovery for High throughput screening campaigns.
Type:
CRO / CMO
Enabling Technologies
|
 |
CIBER |
Enabling Technologies
Others |
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine |
1R+D |
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Type:
Enabling Technologies
Others
|
|
CIBER |
Others |
NewroPharma: A Target Validation Platform, provide a comprehensive list of preclinical drug development services to pharmaceutical partners. |
2PreV |
NewroPharma: A Target Validation Platform, provide a comprehensive list of preclinical drug development services to pharmaceutical partners.
Type:
Others
|
|
CIBER |
CRO / CMO
Enabling Technologies
Screening |
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine |
2PreV |
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
CIBER |
Others |
Bilateral Pupillometry Platform for small Animals |
2PreV |
Bilateral Pupillometry Platform for small Animals
Type:
Others
|
|
CIBER |
CRO / CMO
Enabling Technologies |
Preclinical Validation-Tissue, Biomaterial and Surface Characterization |
2PreV |
Preclinical Validation-Tissue, Biomaterial and Surface Characterization
Type:
CRO / CMO
Enabling Technologies
|
|
CIBER |
CRO / CMO
Enabling Technologies
Others |
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates |
5RTM |
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates
Type:
CRO / CMO
Enabling Technologies
Others
|
|
CIBER |
CRO / CMO
Enabling Technologies
Others |
Production of Customized Biomolecules (Antibodies, Proteins and Peptides) |
5RTM |
Production of Customized Biomolecules (Antibodies, Proteins and Peptides)
Type:
CRO / CMO
Enabling Technologies
Others
|
 |
Enzymlogic |
CRO / CMO
Screening |
KINETICfinder® is a high throughput kinetic platform that delivers all key binding kinetics (kon, koff, residence time) and affinity (Kd) parameters for reversible binders quickly and at scale. >115 targets established, including wt, clinically relevant |
5RTM |
KINETICfinder® is a high throughput kinetic platform that delivers all key binding kinetics (kon, koff, residence time) and affinity (Kd) parameters for reversible binders quickly and at scale. >115 targets established, including wt, clinically relevant
Type:
CRO / CMO
Screening
|
|
Enzymlogic |
CRO / CMO
Screening |
COVALfinder® is a robust kinetic platform that delivers all key inactivation (kinact, kinact/KI, T1/2∞) and affinity (KI) parameters for irreversible binders. More than 20 targets established on COVALfinder®, including wt and clinically relevant muta |
5RTM |
COVALfinder® is a robust kinetic platform that delivers all key inactivation (kinact, kinact/KI, T1/2∞) and affinity (KI) parameters for irreversible binders. More than 20 targets established on COVALfinder®, including wt and clinically relevant muta
Type:
CRO / CMO
Screening
|
 |
FUND. PROGRESO Y SALUD |
Enabling Technologies |
Hybridome/Antibody Production Platform |
1R+D |
Hybridome/Antibody Production Platform
Type:
Enabling Technologies
|
|
FUND. PROGRESO Y SALUD |
CRO / CMO |
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials |
3CV |
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials
Type:
CRO / CMO
|
|
FUND. PROGRESO Y SALUD |
Drug Delivery |
Liposome delivery System (Prostate Cancer) |
1R+D |
Liposome delivery System (Prostate Cancer)
Type:
Drug Delivery
|
|
FUND. PROGRESO Y SALUD |
Screening |
Screening Cell lines & Animal Models |
1R+D |
Screening Cell lines & Animal Models
Type:
Screening
|
|
FUND. PROGRESO Y SALUD |
CRO / CMO |
Andalusian's genomics and bioinformatic platform / Nanoimaging & Metabolomic platform / Biobank |
5RTM |
Andalusian's genomics and bioinformatic platform / Nanoimaging & Metabolomic platform / Biobank
Type:
CRO / CMO
|
 |
Fundacion MEDINA |
CRO / CMO |
Chemical Isolation & Structural Elucidation of natural products |
3CV |
Chemical Isolation & Structural Elucidation of natural products
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Enabling Technologies
Screening |
Mass spectrometry metabolomics |
1R+D |
Mass spectrometry metabolomics
Type:
Enabling Technologies
Screening
|
|
Fundacion MEDINA |
CRO / CMO |
Microbial and Mammalian cell culturing |
3CV |
Microbial and Mammalian cell culturing
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Screening |
High throughput imaging platform for phenotypic drug discovery |
2PreV |
High throughput imaging platform for phenotypic drug discovery
Type:
Screening
|
|
Fundacion MEDINA |
Screening |
Microbial Natural Product Libraries |
3CV |
Microbial Natural Product Libraries
Type:
Screening
|
|
Fundacion MEDINA |
CRO / CMO |
Preclinical Safety Platform |
3CV |
Preclinical Safety Platform
Type:
CRO / CMO
|
|
Fundacion MEDINA |
CRO / CMO |
Bioanalytical Platform |
3CV |
Bioanalytical Platform
Type:
CRO / CMO
|
|
Fundacion MEDINA |
Screening |
High throughput screening platform for drug discovery |
3CV |
High throughput screening platform for drug discovery
Type:
Screening
|
 |
Histocell |
CRO / CMO |
GMP Cell Bank Therapy Manufacturing (MCB, WCB) |
5RTM |
GMP Cell Bank Therapy Manufacturing (MCB, WCB)
Type:
CRO / CMO
|
|
Histocell |
CRO / CMO |
GMP Cell Therapy Manufacturing (DS & DP) |
5RTM |
GMP Cell Therapy Manufacturing (DS & DP)
Type:
CRO / CMO
|
|
Histocell |
CRO / CMO |
GMP Biological Product Manufacturing from Human Cells (DS & DP) |
5RTM |
GMP Biological Product Manufacturing from Human Cells (DS & DP)
Type:
CRO / CMO
|
 |
IIS La Fe |
Enabling Technologies
Screening |
Biotechnology platform: Expression and purification of recombinant proteins. Fragment-based screening |
1R+D |
Biotechnology platform: Expression and purification of recombinant proteins. Fragment-based screening
Type:
Enabling Technologies
Screening
|
|
IIS La Fe |
Screening |
Analytical Unit certified GLP: Targeted and untargeted metabolic studies by combination of chromatography and mass spectrometry techniques |
3CV |
Analytical Unit certified GLP: Targeted and untargeted metabolic studies by combination of chromatography and mass spectrometry techniques
Type:
Screening
|
|
IIS La Fe |
CRO / CMO
Drug Delivery |
Advanced Therapies Unit: offers services that require specially designed infrastructures under the most demanding regulatory framework for the development of pre-clinical and clinical studies within the Advanced Therapies programs. |
5RTM |
Advanced Therapies Unit: offers services that require specially designed infrastructures under the most demanding regulatory framework for the development of pre-clinical and clinical studies within the Advanced Therapies programs.
Type:
CRO / CMO
Drug Delivery
|
|
IIS La Fe |
Enabling Technologies |
Experimental Radiology and Imaging Biomarkers Platform: MR imaging acquisition, image acquisition US, angiographic studies and processing by large and small animal imaging (3 Tesla Magnetic Resonance Unit,etc.) |
1R+D |
Experimental Radiology and Imaging Biomarkers Platform: MR imaging acquisition, image acquisition US, angiographic studies and processing by large and small animal imaging (3 Tesla Magnetic Resonance Unit,etc.)
Type:
Enabling Technologies
|
|
IIS La Fe |
Enabling Technologies |
Pharmacogenetics. Experimental design, polymorphism determination (mainly SNP) in relation to drug response, DNA extraction from blood samples and farmacogenetics consulting and report writing. |
1R+D |
Pharmacogenetics. Experimental design, polymorphism determination (mainly SNP) in relation to drug response, DNA extraction from blood samples and farmacogenetics consulting and report writing.
Type:
Enabling Technologies
|
|
IIS La Fe |
Screening |
Epigenomics Unit: DNA methylation and histone modifications at a genomic scale. High-performance technologies based on arrays of methylation and chromatin immunoprecipitation (ChIP) analysis. Any kind of samples (FFPE and frozen tumour). |
2PreV |
Epigenomics Unit: DNA methylation and histone modifications at a genomic scale. High-performance technologies based on arrays of methylation and chromatin immunoprecipitation (ChIP) analysis. Any kind of samples (FFPE and frozen tumour).
Type:
Screening
|
|
IIS La Fe |
CRO / CMO |
Biobank. Third level regulated biobank able to manage biological samples, clinical (and non-clinical) data. |
1R+D |
Biobank. Third level regulated biobank able to manage biological samples, clinical (and non-clinical) data.
Type:
CRO / CMO
|
|
IIS La Fe |
Enabling Technologies |
Platform for Health ICT: Big Data and Digital Health.Treatment of large amounts of data (RWD) and development of methodologies and tools to support clinical decisions |
2PreV |
Platform for Health ICT: Big Data and Digital Health.Treatment of large amounts of data (RWD) and development of methodologies and tools to support clinical decisions
Type:
Enabling Technologies
|
|
IIS La Fe |
Enabling Technologies |
Innovatives drugs. RMN, biophisical, biochemical (molecular and cellular biology) and computational (QSAR, docking, structural modeling) methods for development of novel drugs and biomarkers identification. |
1R+D |
Innovatives drugs. RMN, biophisical, biochemical (molecular and cellular biology) and computational (QSAR, docking, structural modeling) methods for development of novel drugs and biomarkers identification.
Type:
Enabling Technologies
|
|
IIS La Fe |
CRO / CMO |
Animal experimentation capabilities. Personalised consulting and regulating service, animal research experimentation optimization. |
1R+D |
Animal experimentation capabilities. Personalised consulting and regulating service, animal research experimentation optimization.
Type:
CRO / CMO
|
|
IIS La Fe |
CRO / CMO |
Clinical and Products with Biological Activity Research Unit (UICAB): Participates in the development of clinical studies aimed at different pathologies, providing healthcare support in highly complex studies, such as Clinical Trials in early phases |
5RTM |
Clinical and Products with Biological Activity Research Unit (UICAB): Participates in the development of clinical studies aimed at different pathologies, providing healthcare support in highly complex studies, such as Clinical Trials in early phases
Type:
CRO / CMO
|
|
IIS La Fe |
Enabling Technologies |
Microscopy. Offers the infraestructure for a developing wide variety of microscopy techniques. Optic microscopy, cryostat, bright field microscope, fluorescence microscope, confocal, ultramicrotome, etc. |
1R+D |
Microscopy. Offers the infraestructure for a developing wide variety of microscopy techniques. Optic microscopy, cryostat, bright field microscope, fluorescence microscope, confocal, ultramicrotome, etc.
Type:
Enabling Technologies
|
|
IIS La Fe |
Enabling Technologies |
Data Science, Biostatistics and Bioinformatics Unit: unsupervised analysis (clustering, PCA, SOM), analysis of omic data, simulation techniques (Monte Carlo) and resampling (Bootstrapping), R Programming, etc. |
1R+D |
Data Science, Biostatistics and Bioinformatics Unit: unsupervised analysis (clustering, PCA, SOM), analysis of omic data, simulation techniques (Monte Carlo) and resampling (Bootstrapping), R Programming, etc.
Type:
Enabling Technologies
|
|
IIS La Fe |
Screening |
Cytomics Unit: FACSAria-III cell sorter, FACSCanto-II flow cytometer and two high-content screening systems (Scan^R, Olympus, and InCell Analyzer, GE) |
1R+D |
Cytomics Unit: FACSAria-III cell sorter, FACSCanto-II flow cytometer and two high-content screening systems (Scan^R, Olympus, and InCell Analyzer, GE)
Type:
Screening
|
|
IIS La Fe |
|
Biolectronics, Signal Processing and Algorithmy Unit: provides support in the development of medical devices related to advanced signal processing, for the optimization of diagnostics and therapeutic applications. |
1R+D |
Biolectronics, Signal Processing and Algorithmy Unit: provides support in the development of medical devices related to advanced signal processing, for the optimization of diagnostics and therapeutic applications.
Type:
|
|
IIS La Fe |
Screening |
Genomic Unit: Next Generation Sequencing by Nexseq500 (Illumina), Ion PGM and Ion Proton. Arrays services by Affymetrix Platform |
1R+D |
Genomic Unit: Next Generation Sequencing by Nexseq500 (Illumina), Ion PGM and Ion Proton. Arrays services by Affymetrix Platform
Type:
Screening
|
 |
IMMUNOSTEP |
Enabling Technologies |
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems |
2PreV |
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems
Type:
Enabling Technologies
|
|
IMMUNOSTEP |
Enabling Technologies |
This kit is intended for RUO in the purification and identification of human exosomes from Cell Culture, Blood and Urine samples, For flow cytometric detection. |
5RTM |
This kit is intended for RUO in the purification and identification of human exosomes from Cell Culture, Blood and Urine samples, For flow cytometric detection.
Type:
Enabling Technologies
|
 |
InnoUp Farma |
Others |
Oral nanoparticles-based platform with the capacity to modulate the immune response and to increase drug bioavailability |
3CV |
Oral nanoparticles-based platform with the capacity to modulate the immune response and to increase drug bioavailability
Type:
Others
|
 |
Institut Quimic de Sarrià (IQS) |
CRO / CMO
Drug Delivery
Enabling Technologies |
Peptides. Design, optimization and production of peptides and conjugates. |
1R+D |
Peptides. Design, optimization and production of peptides and conjugates.
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
|
|
Institut Quimic de Sarrià (IQS) |
CRO / CMO
Drug Delivery
Enabling Technologies
Others |
Biomaterials and Nanomaterials. Development of nanomaterials and nanoparticles. Biopolymers and lipidic vesicles. |
5RTM |
Biomaterials and Nanomaterials. Development of nanomaterials and nanoparticles. Biopolymers and lipidic vesicles.
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Others
|
|
Institut Quimic de Sarrià (IQS) |
CRO / CMO |
Animal cell bioprocess. Production of biomolecules. Process development & optimization. Bioreactors. |
5RTM |
Animal cell bioprocess. Production of biomolecules. Process development & optimization. Bioreactors.
Type:
CRO / CMO
|
|
Institut Quimic de Sarrià (IQS) |
CRO / CMO
Screening |
Analytics. GMP Analytical services: Development and routine analysis of bioproducts. |
1R+D |
Analytics. GMP Analytical services: Development and routine analysis of bioproducts.
Type:
CRO / CMO
Screening
|
 |
IRYCIS |
Others
Screening |
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response |
3CV |
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response
Type:
Others
Screening
|
 |
Kinsy |
CRO / CMO |
Process Development / Optimisation / Scale up / Technology Transfer (Fine Chemical) |
5RTM |
Process Development / Optimisation / Scale up / Technology Transfer (Fine Chemical)
Type:
CRO / CMO
|
|
Kinsy |
CRO / CMO |
GMP Clinical and Commercial Manufacturing Services (Fine Chemical) |
5RTM |
GMP Clinical and Commercial Manufacturing Services (Fine Chemical)
Type:
CRO / CMO
|
|
Kinsy |
CRO / CMO |
Analytical Methods - Development and Validation |
5RTM |
Analytical Methods - Development and Validation
Type:
CRO / CMO
|
|
Kinsy |
CRO / CMO |
Stability Studies Servicies |
5RTM |
Stability Studies Servicies
Type:
CRO / CMO
|
|
Kinsy |
CRO / CMO |
Cryogenic reaction capabilities - Laboratory scale to (GMP) 250L |
5RTM |
Cryogenic reaction capabilities - Laboratory scale to (GMP) 250L
Type:
CRO / CMO
|
|
Kinsy |
CRO / CMO |
Flash Chromatography Units (75/150/400 systems) - Fast Purification (15g - 10Kg) |
5RTM |
Flash Chromatography Units (75/150/400 systems) - Fast Purification (15g - 10Kg)
Type:
CRO / CMO
|
 |
Laminar Pharma |
Enabling Technologies |
Membrane-Lipid Therapy (MLT), a novel therapeutic approach targeting lipid metabolism |
3CV |
Membrane-Lipid Therapy (MLT), a novel therapeutic approach targeting lipid metabolism
Type:
Enabling Technologies
|
 |
Leitat |
CRO / CMO
Enabling Technologies
Screening |
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling, humanised pseudogerm-free murine models)
Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient |
5RTM |
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling, humanised pseudogerm-free murine models)
Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling).
Studies of proliferation, viability, apoptosis, migration, invasion, wound healing, adhesion, and many others in monolayer cell cultures of primary cells. |
5RTM |
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling).
Studies of proliferation, viability, apoptosis, migration, invasion, wound healing, adhesion, and many others in monolayer cell cultures of primary cells.
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
|
Leitat |
CRO / CMO
Drug Delivery
Enabling Technologies
Screening |
Polyclonal & Monoclonal Antibody Generation and Production Platform.
Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab)2, scFv, Conjugation, ELISA |
5RTM |
Polyclonal & Monoclonal Antibody Generation and Production Platform.
Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab)2, scFv, Conjugation, ELISA
Type:
CRO / CMO
Drug Delivery
Enabling Technologies
Screening
|
 |
LIbera Bio |
Drug Delivery |
MPN Technology® is a nanotechnology platform that allows for the efficient encapsulation of a variety of anticancer compounds (“payload” of biologic -monoclonal antibodies, proteins, RNA- or small molecule) and their precise delivery to tumor cells |
1R+D |
MPN Technology® is a nanotechnology platform that allows for the efficient encapsulation of a variety of anticancer compounds (“payload” of biologic -monoclonal antibodies, proteins, RNA- or small molecule) and their precise delivery to tumor cells
Type:
Drug Delivery
|
 |
Microomics Systems |
CRO / CMO
Enabling Technologies
Screening |
High quality metagenomics, genomics and transcriptomics services to companies industrial research centers in the fields of: pre and probiotics, metabolic studies, human and animal health, dental treatments and agriculture solutions (biofertilizers) |
5RTM |
High quality metagenomics, genomics and transcriptomics services to companies industrial research centers in the fields of: pre and probiotics, metabolic studies, human and animal health, dental treatments and agriculture solutions (biofertilizers)
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
NEURAL THERAPIES |
CRO / CMO |
Screening of molecules as neuroprotectors, mainly in cerebrovascular and Alzheimer diseases. Evaluation on infarct volume, behavioral responses, inflammation, homeostatic response and cell death.
Models: Focal ischemia, global ischemia, oxygen and OGD. |
1R+D |
Screening of molecules as neuroprotectors, mainly in cerebrovascular and Alzheimer diseases. Evaluation on infarct volume, behavioral responses, inflammation, homeostatic response and cell death.
Models: Focal ischemia, global ischemia, oxygen and OGD.
Type:
CRO / CMO
|
 |
OPERON |
Screening |
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections |
5RTM |
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections
Type:
Screening
|
 |
PROMEGA BIOTECH IBÉRICA |
Enabling Technologies |
Maxprep Liquid Handler, robotic Nucleic Acid Purification System |
5RTM |
Maxprep Liquid Handler, robotic Nucleic Acid Purification System
Type:
Enabling Technologies
|
|
PROMEGA BIOTECH IBÉRICA |
Enabling Technologies
Screening |
GloMax Discover Microplate Reader. Multimode Plate Reader for luminescence, fluorescence and absorbance measurements |
5RTM |
GloMax Discover Microplate Reader. Multimode Plate Reader for luminescence, fluorescence and absorbance measurements
Type:
Enabling Technologies
Screening
|
|
PROMEGA BIOTECH IBÉRICA |
CRO / CMO
Enabling Technologies |
Custom Manufacturing. We apply our knowledge and experience in technology development, manufacturing and quality systems with a cross-functional team of peers to comply with international quality standards (ISO) and produce custom products that will be ma |
5RTM |
Custom Manufacturing. We apply our knowledge and experience in technology development, manufacturing and quality systems with a cross-functional team of peers to comply with international quality standards (ISO) and produce custom products that will be ma
Type:
CRO / CMO
Enabling Technologies
|
 |
Sylentis |
Others |
SIRFINDER(TM). RNA interference prediction software based on artificial intelligence (AI) to design the best candidates for a specific target and to predict inhibition efficiency with improved specificity and sensitivity. |
5RTM |
SIRFINDER(TM). RNA interference prediction software based on artificial intelligence (AI) to design the best candidates for a specific target and to predict inhibition efficiency with improved specificity and sensitivity.
Type:
Others
|
 |
VIVEBIOTECH |
CRO / CMO |
Development of more cost-effective gene therapy processes |
3CV |
Development of more cost-effective gene therapy processes
Type:
CRO / CMO
|
|
VIVEBIOTECH |
CRO / CMO |
LENTISOMA platform: for the R&D manufacture of lentiviral vectors with an enhanced safety profile. |
3CV |
LENTISOMA platform: for the R&D manufacture of lentiviral vectors with an enhanced safety profile.
Type:
CRO / CMO
|
 |
Vivia Biotech |
CRO / CMO
Enabling Technologies
Screening |
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations |
5RTM |
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations
Type:
CRO / CMO
Enabling Technologies
Screening
|
 |
ZeClinics |
CRO / CMO
Screening |
ZeTox platform is a portfolio of in vivo toxicity testing services. We conduct high throughput safety screenings of novel drugs and chemicals with potential human or environmental risks using zebrafish at different developmental stages. |
5RTM |
ZeTox platform is a portfolio of in vivo toxicity testing services. We conduct high throughput safety screenings of novel drugs and chemicals with potential human or environmental risks using zebrafish at different developmental stages.
Type:
CRO / CMO
Screening
|
|
ZeClinics |
CRO / CMO
Enabling Technologies
Screening |
ZeGenesis platform is a portfolio of genetic services for the generation of zebrafish lines, including but not limited to mutagenesis (Knock-out, Knock-In) and transgenesis or cell lines through CRISPR/Cas9, as well as gene expression modulation studies. |
5RTM |
ZeGenesis platform is a portfolio of genetic services for the generation of zebrafish lines, including but not limited to mutagenesis (Knock-out, Knock-In) and transgenesis or cell lines through CRISPR/Cas9, as well as gene expression modulation studies.
Type:
CRO / CMO
Enabling Technologies
Screening
|
|
ZeClinics |
CRO / CMO
Enabling Technologies
Screening |
ZeEfficacy platform is a portfolio of zebrafish solutions, including ready-to-use disease models and high throughput phenotypic and behavioral screening for drug discovery and functional genetic studies. |
5RTM |
ZeEfficacy platform is a portfolio of zebrafish solutions, including ready-to-use disease models and high throughput phenotypic and behavioral screening for drug discovery and functional genetic studies.
Type:
CRO / CMO
Enabling Technologies
Screening
|